Trial results for a real-world study on the 2-drug regimen Dolutegravir + Lamivudine (DTG+3TC) in patients with HIV were posted on ClinicalTrials.gov on 2025-08-17, involving 376 participants.
Background
Human Immunodeficiency Virus (HIV) infection requires ongoing management with antiretroviral therapy (ART). While controlled clinical trials establish efficacy and safety, real-world evidence is crucial for understanding how treatments perform in routine clinical care settings, which often involve a broader and more diverse patient population. This study specifically focused on the 2-drug regimen of Dolutegravir (DTG) and Lamivudine (3TC), aiming to provide insights into its effectiveness and sustainability in Germany for both treatment-naive and pre-treated HIV-1 positive individuals.
Trial design
This completed, prospective, non-interventional, multi-center study enrolled 376 participants with HIV Infections in Germany. The study's objective was to gather real-world evidence on the use of the 2-drug regimen Dolutegravir + Lamivudine (DTG+3TC) in routine clinical care. Participants included both treatment-naive and pre-treated HIV-1 positive individuals, with an observation period of 3 years. Data was collected via an electronic data capture system.
Key results
The study reported several key measurements regarding the effectiveness and sustainability of the DTG+3TC regimen in routine clinical care:
- Percentage of Participants With Low Level Viremia:
- For ART-naive participants, reported percentages were 3.2, 6.5, and 3.2.
- For pre-treated participants, reported percentages were 1.8, 1.5, 0.9, and 1.8.
- Percentage of Participants With Virologic Rebound:
- In ART-naive participants: 3.4 percent.
- In pre-treated participants: 0.3 percent.
- Percentage of Participants With Treatment Switch Due to Virologic Reasons or Due to Intolerability:
- In ART-naive participants: 3.2 percent.
- In pre-treated participants: 1.5 percent.
What this means
The real-world data from this German study provides valuable insights into the performance of the Dolutegravir + Lamivudine (DTG+3TC) 2-drug regimen for HIV management. The reported low percentages of participants experiencing low level viremia, virologic rebound, and treatment switches due to virologic reasons or intolerability suggest that this regimen demonstrates favorable effectiveness and sustainability in routine clinical care for both ART-naive and pre-treated individuals. These findings complement controlled trial data, reinforcing the utility of DTG+3TC in a broader patient population.
Source
The information regarding these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for the study titled "Description of Real World Antiviral Effectiveness and Sustainability of the 2-Drug Regimen Dolutegravir + Lamivudine in Untreated and Pre-treated Patients in Routine Clinical Care in Germany" were posted on 2025-08-17 on clinicaltrials.gov.